Genetics firms push back on FDA crackdown

Last month, the FDA started quietly cracking down on genetic testing companies offering results on whether patients’ DNA might make it unwise to take certain drugs. Now the industry is pushing back.

As STAT’s Rebecca Robbins reports, a trade group that represents clinical laboratories sent a stern letter to regulators, warning that the FDA’s move could stifle a growing industry and make it harder for patients to get the right types and doses of their medications.

Whether the letter goes anywhere remains to be seen, but its author, the American Clinical Laboratory Association, requests a meeting with the FDA and a legislative solution to clear up the rules around pharmacogenetic testing.

Read more.